Lotte Biologics receives usage approval for Songdo Bio Campus Plant 1

▤ Summary

Lotte Biologics has received usage approval for the first plant at its Songdo Bio Campus. The company completed the main construction work roughly two years after breaking ground and now plans to begin trial runs and validation in the second half of the year. The facility is built for 120,000 liters of antibody drug production capacity and includes automation, monitoring, and digital manufacturing systems. The site is designed to support both early-stage clinical supply and large-scale commercial CDMO demand through a dual-site model with its Syracuse campus. This move strengthens its production base and signals upcoming operational ramp-up for customers and partners in life sciences manufacturing.

▦ Linked Companies